Oct 23 2009, 11:43 AM EST
GEN News Highlights
EMD Chemicals reported a research and commercial collaboration with MitoSciences related to the detection and profiling of mitochondrial toxicity and activity. The companies will co-develop multiplex immunoassay products for EMD Chemicals' WideScreen™ BeadPlex™ platform.
The first set of assays is scheduled for availability in early 2010. The kits will be sold to pharmaceutical and biotechnology companies as well as academic institutions. EMD Chemicals and MitoSciences will continue to collaborate to design, create, and release new products that meet the evolving requirements of their customers.
Under the terms of the agreement, MitoSciences granted EMD Chemicals exclusive rights to a new offering of currently unlicensed mAbs for monitoring mitochondrial toxicity and bioactivity. MitoSciences will work exclusively with EMD Chemicals to validate the new WideScreen™ assays for use in drug-screening applications.
“MitoSciences has long been aware of the need for multiplex immunoassay panels against mitochondrial and other metabolic proteins,” comments Jean-Paul Audette, president and CEO.
Christina Shasserre, vp and head of global biosciences for Merck KGaA and EMD Chemicals, adds, “To develop safer drugs and save time and resources in the process, the evaluation of toxicity is a clear focus in preclinical drug development. Testing the effect of drug candidates on mitochondrial processes such as metabolism and replication as an important aspect of toxicity profiling.”
♦♦♦
Related News
MitoSciences Secures University of Oregon mAbs Related to Mitochondrial Research for $4.6M (Apr. 16, 2008)
Invitrogen to Take Over Distribution of MitoSciences’ Products in North America (Apr. 9, 2008)
Rules-Based Medicine Partners with EMD to Work on Multianalyte Kits for Biomarkers (Dec. 12, 2007)
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
News
Articles
Blogs